Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tenaya Therapeutics, Inc.TNYA · Entity 6506 | Director | May 28, 2026 | May 29, 2026 |
| bluebird bio, Inc.BLUE · Entity 78923 | Chief Strategy Officer | August 20, 2019 | August 21, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tenaya Therapeutics, Inc.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2036-05-27 | Direct | 120,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 120,000 · Balance 120,000 F1: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.
bluebird bio, Inc.
Report date August 20, 2019 · Filed August 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,921 |
Ending reported balance
After 2019-08-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-08-20 · Exercise / conversion · Acquired 500 · Balance 41,421 Row 2 · 2019-08-20 · Sale · Disposed 500 · Balance 40,921 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 16, 2019. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.47 · Expires 2024-03-03 | Direct | 9,521 |
Reported balance
After 2019-08-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-08-20 · Exercise / conversion · Disposed 500 · Balance 9,521 F2: This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 16, 2019.
F2: This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2018 Filed Sep 12, 2018 16:12 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 700 | $150.24 | $105,164.99 |
DisclosureSEC source: 0001209191-18-050632 · doc4.xml · nonDerivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,495 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F3 · price: The range of prices for the transaction reported on this line was $150.00 to $150.65. The average weighted price was $150.2357. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 16:12 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 501 | $149.22 | $74,759.77 |
DisclosureSEC source: 0001209191-18-050632 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,494 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F2 · price: The range of prices for the transaction reported on this line was $149.00 to $149.75. The average weighted price was $149.2211. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 16:12 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 1,500 | $24.47 | $36,705.00 |
DisclosureSEC source: 0001209191-18-050632 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 17:03 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 7,250 | $0.00 Strike: $24.47 | $0.00 |
DisclosureSEC source: 0001209191-18-049247 · doc4.xml · derivative · entry 8 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,021 Underlying: Common Stock · 7,250 shares Expires 2024-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 17:03 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 4,007 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001209191-18-049247 · doc4.xml · derivative · entry 7 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,007 shares Expires 2023-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013 and April 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014 and April 1, 2014, respectively, with the remainder of the shares vesting in equal monthly installments over the following three years. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 17:03 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 8,743 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001209191-18-049247 · doc4.xml · derivative · entry 6 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,743 shares Expires 2021-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vested over a four-year period, at a rate of twenty-five percent (25%) on May 16, 2012 and in 36 equal monthly installments thereafter. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 17:03 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 978 | $176.03 | $172,154.70 |
DisclosureSEC source: 0001209191-18-049247 · doc4.xml · nonDerivative · entry 5 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,495 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F3 · price: The range of prices for the transaction reported on this line was $176.00 to $176.20. The average weighted price was $176.0273. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 17:03 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 19,022 | $175.37 | $3,335,793.03 |
DisclosureSEC source: 0001209191-18-049247 · doc4.xml · nonDerivative · entry 4 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,473 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F2 · price: The range of prices for the transaction reported on this line was $175.00 to $175.95. The average weighted price was $175.365. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 17:03 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 7,250 | $24.47 | $177,407.50 |
DisclosureSEC source: 0001209191-18-049247 · doc4.xml · nonDerivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 17:03 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 4,007 | $5.50 | $22,040.10 |
DisclosureSEC source: 0001209191-18-049247 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 17:03 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 8,743 | $2.09 | $18,241.40 |
DisclosureSEC source: 0001209191-18-049247 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 16:47 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001209191-18-046622 · doc4.xml · derivative · entry 6 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,007 Underlying: Common Stock · 1,500 shares Expires 2023-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 16:47 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 105 | $158.57 | $16,649.50 |
DisclosureSEC source: 0001209191-18-046622 · doc4.xml · nonDerivative · entry 5 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,495 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F5 · price: The range of prices for the transaction reported on this line was $158.55 to $158.90. The average weighted price was $158.5667. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 16:47 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 620 | $157.86 | $97,872.02 |
DisclosureSEC source: 0001209191-18-046622 · doc4.xml · nonDerivative · entry 4 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,600 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F4 · price: The range of prices for the transaction reported on this line was $157.30 to $158.20. The average weighted price was $157.8581. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 16:47 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 350 | $156.63 | $54,820.26 |
DisclosureSEC source: 0001209191-18-046622 · doc4.xml · nonDerivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,220 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F3 · price: The range of prices for the transaction reported on this line was $156.20 to $156.95. The average weighted price was $156.6293. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 16:47 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 425 | $155.41 | $66,047.51 |
DisclosureSEC source: 0001209191-18-046622 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,570 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F2 · price: The range of prices for the transaction reported on this line was $155.15 to $156.05. The average weighted price was $155.4059. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 16:47 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 1,500 | $5.50 | $8,250.60 |
DisclosureSEC source: 0001209191-18-046622 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 16:10 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 21,500 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001209191-18-045510 · doc4.xml · derivative · entry 8 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,507 Underlying: Common Stock · 21,500 shares Expires 2023-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013 and as of May 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014 and May 1, 2014, respectively, with the remainder of the shares vesting in equal monthly installments over the following three years. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 16:10 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 500 | $155.42 | $77,710.00 |
DisclosureSEC source: 0001209191-18-045510 · doc4.xml · nonDerivative · entry 7 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,495 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F7 · price: The range of prices for the transaction reported on this line was $155.35 to $155.55. The average weighted price was $155.42. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 16:10 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 3,100 | $154.58 | $479,194.90 |
DisclosureSEC source: 0001209191-18-045510 · doc4.xml · nonDerivative · entry 6 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,995 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F6 · price: The range of prices for the transaction reported on this line was $154.00 to $154.95. The average weighted price was $154.5790. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 16:10 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 3,358 | $153.35 | $514,939.90 |
DisclosureSEC source: 0001209191-18-045510 · doc4.xml · nonDerivative · entry 5 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,095 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F5 · price: The range of prices for the transaction reported on this line was $153.00 to $153.95. The average weighted price was $153.3472. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 16:10 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 2,601 | $152.51 | $396,687.35 |
DisclosureSEC source: 0001209191-18-045510 · doc4.xml · nonDerivative · entry 4 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,453 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F4 · price: The range of prices for the transaction reported on this line was $152.00 to $152.95. The average weighted price was $152.5134. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 16:10 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 3,976 | $151.59 | $602,712.30 |
DisclosureSEC source: 0001209191-18-045510 · doc4.xml · nonDerivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,054 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F3 · price: The range of prices for the transaction reported on this line was $151.00 to $151.95. The average weighted price was $151.5876. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 16:10 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 7,965 | $150.31 | $1,197,248.62 |
DisclosureSEC source: 0001209191-18-045510 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,030 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F2 · price: The range of prices for the transaction reported on this line was $150.00 to $150.95. The average weighted price was $150.3137. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 16:10 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 21,500 | $5.50 | $118,258.60 |
DisclosureSEC source: 0001209191-18-045510 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 16:04 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $205.25 | $0.00 |
DisclosureSEC source: 0001209191-18-007412 · doc4.xml · derivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-02-01 F2 · derivative.exercise_date: This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2019, and in 36 equal monthly installments. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 16:04 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-007412 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,495 F1 · security: Restricted stock units for common stock vest over a four-year period at a rate of 25% on 01/04/2019, 25% on 01/04/2020, 25% on 01/04/2021, and 25% on 01/04/2022. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 16:07 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 401 | $174.17 | $69,842.33 |
DisclosureSEC source: 0001209191-18-002906 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,245 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F3 · price: The range in prices for the transaction reported on this line was $173.85 to $174.35. The average weighted price was $174.1704. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 16:07 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 2,659 | $173.26 | $460,687.97 |
DisclosureSEC source: 0001209191-18-002906 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,646 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $172.85 to $173.80. The average weighted price was $173.2561. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 9,900 | $0.00 Strike: $24.47 | $0.00 |
DisclosureSEC source: 0001209191-17-065414 · doc4.xml · derivative · entry 12 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,271 Underlying: Common Stock · 9,900 shares Expires 2024-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,420 | $221.52 | $314,554.00 |
DisclosureSEC source: 0001209191-17-065414 · doc4.xml · nonDerivative · entry 11 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,305 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F11 · price: The range of prices for the transaction reported on this line was $221.3000 to $221.6750. The average weighted price was $221.5169. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 680 | $220.52 | $149,954.01 |
DisclosureSEC source: 0001209191-17-065414 · doc4.xml · nonDerivative · entry 10 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,725 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F10 · price: The range of prices for the transaction reported on this line was $220.1500 to $221.0500. The average weighted price was $220.5206. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 800 | $219.49 | $175,588.40 |
DisclosureSEC source: 0001209191-17-065414 · doc4.xml · nonDerivative · entry 9 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,405 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F9 · price: The range of prices for the transaction reported on this line was $219.0000 to $219.7000. The average weighted price was $219.4855. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 950 | $218.09 | $207,185.03 |
DisclosureSEC source: 0001209191-17-065414 · doc4.xml · nonDerivative · entry 8 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,205 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F8 · price: The range of prices for the transaction reported on this line was $218.0000 to $218.2500. The average weighted price was $218.0895. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 2,550 | $217.33 | $554,196.09 |
DisclosureSEC source: 0001209191-17-065414 · doc4.xml · nonDerivative · entry 7 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,155 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F7 · price: The range of prices for the transaction reported on this line was $217.0000 to $217.9500. The average weighted price was $217.3318. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 380 | $214.58 | $81,542.00 |
DisclosureSEC source: 0001209191-17-065414 · doc4.xml · nonDerivative · entry 6 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,705 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F6 · price: The range of prices for the transaction reported on this line was $214.4000 to $215.1000. The average weighted price was $214.5842. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 520 | $213.65 | $111,096.02 |
DisclosureSEC source: 0001209191-17-065414 · doc4.xml · nonDerivative · entry 5 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,085 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F5 · price: The range of prices for the transaction reported on this line was $213.1500 to $214.0000. The average weighted price was $213.6462. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,200 | $212.70 | $255,240.48 |
DisclosureSEC source: 0001209191-17-065414 · doc4.xml · nonDerivative · entry 4 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,605 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F4 · price: The range of prices for the transaction reported on this line was $212.1000 to $213.0000. The average weighted price was $212.7004. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 101 | $211.06 | $21,317.00 |
DisclosureSEC source: 0001209191-17-065414 · doc4.xml · nonDerivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,805 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F3 · price: The range of prices for the transaction reported on this line was $211.0500 to $212.0000. The average weighted price was $211.0594. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,299 | $210.25 | $273,112.41 |
DisclosureSEC source: 0001209191-17-065414 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,906 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F2 · price: The range of prices for the transaction reported on this line was $210.0500 to $210.8750. The average weighted price was $210.2482. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:09 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 9,900 | $24.47 | $242,253.00 |
DisclosureSEC source: 0001209191-17-065414 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 16:02 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 7,829 | $0.00 Strike: $24.47 | $0.00 |
DisclosureSEC source: 0001209191-17-060589 · doc4.xml · derivative · entry 9 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,171 Underlying: Common Stock · 7,829 shares Expires 2024-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 16:02 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 578 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001209191-17-060589 · doc4.xml · derivative · entry 8 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,007 Underlying: Common Stock · 578 shares Expires 2023-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option to purchase shares of our common stock granted on January 16, 2013 with performance-based vesting criteria that were met as of April 1, 2013. The shares underlying these options vested as follows: 25% vested on April 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 16:02 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 1,493 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001209191-17-060589 · doc4.xml · derivative · entry 7 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,743 Underlying: Common Stock · 1,493 shares Expires 2021-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option vests over a four-year period, at a rate of twenty-five percent (25%) on May 16, 2012 and in 36 equal monthly installments thereafter. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 16:02 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,200 | $150.18 | $180,219.96 |
DisclosureSEC source: 0001209191-17-060589 · doc4.xml · nonDerivative · entry 6 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,305 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F4 · price: The range of prices for the transaction reported on this line was $150.1000 to $150.2750. The average weighted price was $150.1833. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 16:02 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 6,600 | $149.74 | $988,259.58 |
DisclosureSEC source: 0001209191-17-060589 · doc4.xml · nonDerivative · entry 5 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,505 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F3 · price: The range of prices for the transaction reported on this line was $149.1000 to $150.0750. The average weighted price was $149.7363. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 16:02 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 2,100 | $148.75 | $312,385.08 |
DisclosureSEC source: 0001209191-17-060589 · doc4.xml · nonDerivative · entry 4 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,105 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016. F2 · price: The range of prices for the transaction reported on this line was $148.1000 to $149.0500. The average weighted price was $148.7548. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 16:02 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 7,829 | $24.47 | $191,575.63 |
DisclosureSEC source: 0001209191-17-060589 · doc4.xml · nonDerivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 16:02 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 578 | $5.50 | $3,179.23 |
DisclosureSEC source: 0001209191-17-060589 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 16:02 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 1,493 | $2.09 | $3,115.00 |
DisclosureSEC source: 0001209191-17-060589 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.